Compare W W Grainger Inc (GWW) vs Hims and Hers Health Inc (HIMS) Price & Performance

GWW trades at $1,398.30, up 1.99% on the day, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company reported robust Q1 2026 earnings of $11.65 per share, beating estimates, and raised its full-year guidance. Revenue growth and profitability remain solid, with a net income margin of 9.7% and ROE of 48.1% for 2025. Recent news highlights its inclusion in high-quality dividend and momentum stock lists, reflecting positive market recognition.

The outlook for GWW is positive, driven by earnings beats and upward guidance revisions, though valuation multiples like a P/E of 36.88 suggest premium pricing. Risks include competitive pressures in the industrial services sector and reliance on MRO market demand. Analyst consensus is cautious with a hold-heavy rating, but the average price target of $1,260 implies modest upside potential from current levels.

Hims & Hers Health trades at $35.52, up 1.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $33.57. Recent earnings show volatility with a Q1 2026 miss, but revenue grew to $2.35 billion in 2025. The company benefits from expansion in weight-loss therapies and a $400 million JPMorgan facility, though high valuations like a P/E of 57.14 and negative net income margin pose concerns.

Outlook is mixed: growth opportunities in telehealth and GLP-1 drugs support upside, but earnings inconsistency and regulatory risks from FDA reviews require caution. Analysts are 35% buy-rated, highlighting potential if execution improves, yet investors face volatility near key resistance at $38.